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Foreword 
 
Over recent years, the field of human medicine has been challenged by the two 
epidemics of heart failure and renal insufficiency (Pokhrel 2008). The coexistence of 
renal and cardiac disease significantly increases mortality and morbidity in human 
patients (Wencker 2007, Ronco 2010).  The heart and kidney are both involved in 
basic physiology, and their functions are strictly linked, that’s why primary disorders 
of heart or kidney often result in secondary dysfunction or injury to the other organ 
(Liang 2008, Ronco 2008, Longhini 2010). The presence of the two problems in the 
same patient is referred as cardiorenal syndrome (CRS). CRS was first described in 
1951 but it’s over the last decade that there has been a growing interest in it (Ledoux 
1951). In veterinary medicine, just little information regarding CRS was available 
(Haggstrom 1996, Atkins 2002, Nicolle 2007). The most common heart disease 
affecting dogs and leading to congestive heart failure, is chronic mitral valve disease 
(CMVD), also known as endocardiosis and myxomatous valve degeneration 
(Haggstrom 2007, Borgarelli 2010).  
This doctoral thesis has been focused over the theme of cardio-renal connection and 
the coexistence of renal insufficiency and heart failure in dogs affected by CMVD. 
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State of the Art 
 
Cardiorenal Syndrome  
Definition and classification 
 
CRS has been used to define different clinical conditions in which heart and kidney 
dysfunction overlap. In 2008, during a Consensus Conference, a new definition of the 
syndrome was proposed by the Acute Dialysis Quality Group (ADQG) (Ronco 2008). 
The ADQG expanded the previous general definition to five subtypes reflecting the 
time-frame of the syndrome and the primacy of organ dysfunction (Ronco 2010).  
CRS are disorders of the heart and kidneys whereby acute or chronic 
dysfunction in one organ may induce acute or chronic dysfunction of the other 
 
The five subtypes of CRS described in literature were:  
CRS type 1 (acute CRS), which is characterized by a rapid worsening of cardiac 
function, leading to acute kidney injury;  
CRS type 2 (chronic CRS), characterized by chronic abnormalities in cardiac function 
causing progressive chronic kidney disease (CKD);  
CRS type 3 (acute renocardiac syndrome), characterized by an abrupt and primary 
worsening of kidney function, leading to acute cardiac dysfunction;  
CRS type 4 (chronic renocardiac syndrome), characterized by a condition of primary 
CKD contributing to decreased cardiac function, ventricular hypertrophy, diastolic 
dysfunction and/or increased risk of adverse cardiovascular events;  
CRS type 5 (secondary CRS), characterized by the presence of combined cardiac and 
renal dysfunction due to acute or chronic systemic disorders (Ronco 2008).  
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Cardiorenal Syndrome  
Type 2 and/or 4 
 
Type-2 CRS is characterized by chronic dysfunction of the heart leading to kidney 
injury or dysfunction, or rather by CKD onset in heart failure patients. Chronic heart 
failure (CHF) and CKD often coexist but it’s still difficult to establish which of these 
two diseases is primary and which is secondary. CKD has been observed in 45% to 
63% of human patients affected by CHF (Ronco 2010). However remains often 
unclear how to classify patients with concomitant CKD and CHF when information 
regarding anamnesis are missing (Bongartz 2005, Bock 2010). The coexistence of 
cardiovascular disease and kidney dysfunction is not enough to diagnose type-2 CRS, 
and two features were proposed in human literature for the diagnosis:  
- CHF and CKD are simultaneously present 
- CHF causally underlies occurrence or progression of CKD. 
 
The most important mechanisms proposed to explain the pathophysiology of type-2 
CRS are: 
- Neurohormonal activation 
- Kidney hypoperfusion 
- Venous congestion 
- Inflammation 
- Atherosclerosis 
- Oxidative stress 
- Recurrent episodes of acute heart and/or kidney decompensation 
 
In particular, kidneys of CHF patients seems to release large amounts of circulating 
renin. The activation of the renin-angiotensyn-aldosteron system (RAAS) causes 
efferent arteriolar constriction, increase in oncotic pressure of peritubular capillaries, 
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nephron-augmented sodium reabsorption, glomerular fibrosis and subsequent 
pressure and volume overload (DiBartola 2007, Polzin 2007, House 2010, Lazzeri 
2011, Colombo 2012, Pierantonazzi 2012, Zatelli 2012). 
 
Type-4 CRS, the chronic renocardiac syndrome, is characterized by cardiovascular 
involvement in patients affected by CKD at any stage according to the National Kidney 
Foundation (NKF) classification in human medicine and to the International Renal 
Interest Society (IRIS) classification in veterinary medicine. The pathophysiologic 
mechanisms that lead to increased cardiovascular risk in CKD patients are still not 
completely known, despite a firm connection between the heart and kidney has been 
established. Loss of kidney function usually leads to the activation of the RAAS and 
the development of arterial hypertension. Hypertension, together with angiotensin 
and aldosterone, accelerates left ventricle hypertrophy and cardiac fibrosis. Recent 
evidence suggests that uremic toxins such as indoxyl sulfate and p-cresol can 
contribute to cardiac fibrosis in renal patients. 
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Cardiorenal Syndrome 
The diagnosis, still a challenge  
 
The diagnosis of type-2/4 CRS is based on the serologic and instrumental diagnosis of 
both chronic heart disease and CKD. In human medicine, cardiac function is more 
widely assessed by NT-proBNP serum levels and echocardiography, whereas the 
estimate glomerular filtration rate (eGFR), serum urea nitrogen (BUN), serum 
creatinine (sCr) and proteinuria represent the most widely used test for the 
evaluation of kidney function. 
 
sCr and BUN 
sCr and BUN are extensively used to quantify renal dysfunction both in human and 
veterinary medicine (Dobre 2012). Considering that in situations of compromised 
renal blood flow, as such as with cardiac disease, the increased reabsorption of urea 
from within the renal tubule leads to serum concentrations increasing 
disproportionately compared to sCr, sCr alone can be elected as a reliable marker of 
renal dysfunction in dogs with CMVD (Medaille 2004, Boswood 2006, Nicolle 2007).  
Worsening renal function (WRF) has been used in human medicine to better control 
the follow up of hospitalized patient and is defined as elevation in sCr. As reported in 
human medicine literature WRF could be defined as an absolute sCr elevation ≥0.3 
mg/dl or 25% relative elevation from baseline (Smith 2003). 
 
eGFR 
Determination of eGFR is a valuable diagnostic tool to investigate renal function in 
humans and companion small animal (Von Hendy 2011). Despite its superiority for 
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detecting early renal dysfunction, measurement of GFR remains an underused tool in 
the diagnosis and management of kidney disease in veterinary medicine. Serum 
creatinine concentration has replaced GFR measurement in most clinical settings 
because of its ease and widespred availability; however, because serum creatinine 
likely does not increase above reference range until approximately 75% of nephrons 
are nonfunctional, the sensitivity and specificity of creatinine for diagnosis of kidney 
disease should be considered inferior to actual determination of GFR (Von Hendy 
2011). 
 
Proteinuria 
In humans the severity of proteinuria is associated with the rate of progression of 
CKD and is a prognostic indicator in individuals with cardiac disease (Harley 2012). 
There is no established cause and effect relationship between proteinuria and the 
progression or development of renal failure in animals. Proteinuria is associated with 
reduced survival, but it is not clear whether the proteinuria is the marker or the 
cause. The urine protein/creatinine ratio (UPC) has become the gold standard test for 
proteinuria and should be run on any patient testing trace or greater on a urine 
dipstick or positive on sulfosalicylic acid (SSA). Ideally, protein is measured over 24-
hour period but this is impractical in animals. The UPC, performed on a single random 
urine sample, has a close correlation to the 24-hour urine protein quantification 
(Grauer 2011, Harley 2012). 
 
Ultrasonography 
Imaging of the heart and the kidney can provide valuable information in the diagnosis 
and management of CRS. Ultrasound based imaging is an essential component in the 
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initial diagnostic workup of CRS; in fact imaging using ultrasound waves is a 
noninvasive, cost-effective and widely available technology (George 2011). 
Echocardiography provides information on the structure and function of the heart, 
and renal ultrasound is useful in differentiating between acute and chronic kidney 
disease and excluding certain causes of acute kidney injury such as obstructive 
uropathy. 
Echocardiography. 
Echocardiography is a safe, noninvasive and reproducible test that provides valuable 
information on the anatomy and function of the heart. Using echocardiography, the 
structure of the myocardium and pericardium, global and regional left ventricle 
function and wall motion can be assessed. Two dimensional, gray-scale, or B mode 
echocardiography provides real-time images of heart structures and their motion. 
Renal Ultrasonography. 
Kidney size and the echogenicity of the renal parenchyma provide useful information 
in the workup of kidney diseases. (Pennink, 2008) Findings related to CKD are: 
decreased or normal renal size, irregularly shaped kidneys, increased echogenicity of 
renal tissue and reduced distinction between medulla and cortex.  
 
Radiography of the thorax 
Thoracic radiographs provide information about heart size, status of pulmonary 
vasculature, and changes in the lungs to help differentiate left-sided congestive heart 
failure from other disease. 
Evaluating the size and shape of the heart silhouette on radiographs is a key step in 
diagnosing and assessing severity of cardiac disease in dogs.  The presence of a 
straight/concave caudal margin of the heart, an elevation of the trachea or an 
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increased vertebral heart score (VHS) should be used along with clinical signs and 
physical exam to determine if CHF treatment is indicated (Guglielmini 2009). 
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Aim of the Study 
 
CRS in dogs affected from CMVD was investigated in a retrospective study and in a 
prospective study. 
 
The retrospective study 
Little information concerning the actual prevalence of renal dysfunction in canine 
patients with naturally occurring heart failure is available (Nicolle 2007). The aims of 
this study were to assess the prevalence of CKD associated with azotemia 
complicating CMVD in dogs,  to evaluate a possible connection between class of 
cardiac failure (ACVIM classification) and class of renal failure (IRIS classification) 
and to investigate the correlation between parameters of renal failure and 
echocardiographic parameters.  
 
The prospective study 
The prospective study is an evaluation of dogs affected by CMVD in ACVIM class B2. 
Recurrent episodes of acute heart and/or kidney failure are considered one of the 
causes leading to worsening renal and heart functions in patients affected by CRS 
type 2/4, the aims of the current study were to assess the influence of heart/kidney 
failure or worsening (defined on echocardiographic, radiographic and laboratory 
parameters) on elected parameters of kidney/heart function in a period of three 
years.  
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Materials and Methods 
 
The retrospective study 
Two thousand two hundred seventy-one records of dogs presented at the Cardiology 
Service of the Department of Veterinary Science and Public Health, University of 
Milan, between January 2003 and December 2012 were retrospectively evaluated. 
The inclusion criteria were: dogs with complete clinical examination (including 
signalment, anamnesis and physical examination findings), thorax radiographs, a 
CMVD diagnosis based on echocardiographic examination (presence of mitral leaflets 
thickening and/or prolapse associated with an abnormal mitral regurgitant jet 
on Doppler color flow imaging) performed by a trained observer, ECG and serum 
biochemical analysis, including serum creatinine (sCr) and serum urea nitrogen 
(BUN) (Atkins 2010). The exclusion criteria were: other heart disease, neoplasm and 
systemic diseases.  Dogs were divided into two groups: dogs receiving therapy for 
medical management of heart failure (therapy-group) and dogs without therapy 
(non-therapy-group) and categorized according to the ACVIM class (Fig.1) and IRIS 
class (Fig.2). 
 
Fig. 1 ACVIM classification (http://cavalierhealth.org/mitral_valve_disease.htm) 
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The prospective study 
Dogs presented at the Cardiology Service of the Department of Veterinary Science and 
Public Health, University of Milan, and at the Cardiology Service of The Department of 
Veterinary Science, University of Parma between July 2012 and May 2013 were 
evaluated. The inclusion criteria (cases) were: dogs with a CMVD diagnosis based on 
echocardiographic examination (presence of mitral leaflets thickening and/or 
prolapse associated with an abnormal mitral regurgitant jet on Doppler color flow 
imaging) performed by trained observers and belonging to ACVIM class B2 (not 
receiving therapy for medical management of heart failure). The exclusion criteria 
Fig. 2 IRIS classification (http://www.iris-kidney.com/) 
19 
 
(cases) were: heart disease different from CMVD, class of heart failure different from 
ACVIM B2, neoplasm, systemic diseases, lower urinary tract disease. Healthy adult 
dogs, older than 6 years, were included in the control group. 
Information obtained from the medical records included signalment, anamnesis and 
physical examination findings. All the dogs (both cases and controls) underwent 
thorax radiography, ECG, serum biochemical analysis, including assessment of serum 
creatinine (sCr), serum urea nitrogen(BUN) and glycaemia (GLY), a complete blood 
count (CBC), urine analysis, urine protein/creatinine ratio (UPC) and indirect 
systemic blood pressure evaluation by Doppler flow meter. Data were collected in a 
dedicated datasheet (Fig.3). Dogs were re-evaluated every 6 month until October 
2014. 
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Fig.3 Datasheet 
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Echocardiography and ECG 
All echocardiographic studies were performed using either a Megas Esaote Cvx 
ultrasound machine (Esaote Medical System) or an Esaote MyLab50 ultrasound 
machine (Esaote Medical System), both equipped with 5-7.5 MHz and 2.5-3 MHz, 
multi-frequency phased array transducers. The dogs were consecutively positioned in 
right and left recumbency. All the echocardiographic measurements were made on 
conscious dogs in accordance with the guidelines of the American Society of 
Echocardiography using the leading-edge to leading-edge method for M-mode 
measurements and the Hansson’s method for the 2D measurements of left atrial (LA) 
and aortic root (Ao) diameters (Thomas et al. 1993, Hannson 2002). 
From the right parasternal short-axis M-mode view at the chordae level, the following 
parameters were obtained:  interventricular septal thickness (IVS), left ventricular 
internal diameter (LVID), and left ventricular posterior wall thickness (LVPW) in 
diastole (d) and systole (s). The following parameters were obtained from 2D views: 
aortic root diameter (Ao) and left atrial diameter (LA) from right parasternal short-
axis view. Mitral valve inflow (E peak velocity - EVmax, A peak velocity – Avmax,  E/A 
ratio), aortic peak velocity (AoVmax) and peak gradient (AoGmax), peak velocity of 
mitral and tricuspid regurgitations (MR and TR) were evaluated using the color 
Doppler and the spectral Doppler (Boon 2011). No angle corrections were needed as 
parallel alignment of the Doppler gate was possible in all dogs. The following 
parameters were calculated: left atrial to aortic root ratio (LA/Ao), fractional 
shortening (FS%), left ventricular ejection fraction (EF%), Endsystolic volume index 
(ESVI), Enddiastolic volume index (EDVI) and Cornell Index calculated over the LVIDd 
(Cornell 2004). The EDVI and ESVI were calculated according to the Teichholz 
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formula, normalized to body surface area (BSA). A standard 6-lead electrocardiogram 
was obtained in awake dogs in order to assess heart rate and diagnose cardiac 
arrhythmias. 
 
Biochemical Analysis 
Blood urea nitrogen (BUN), serum creatinine (sCr) and GLY (only in the prospective 
study) were recorded. Reference intervals for canine BUN and sCr were 20-60 mg/dl 
and <1,4 mg/dl respectively. Dogs were divided into 2 groups: the azotemic (sCr≥1,4 
mg/dl; without reference to BUN values) and the non-azotemic group (sCr<1,4 
mg/dl) (www.iris.kidney.com). 
 
Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics 20 and C5.0 [Release 2.07 
GPL Edition]. Data were analyzed using simple and multiple linear regression test, 
simple and multiple ordinal regression test and Chi Squared test as needed.  A p value 
<0.05 was considered significant.  In the retrospective study the dependent variables 
considered were ACVIM class, IRIS class, BUN and sCr; the independent variables 
considered were all the echocardiographic parameters evaluated, body weight (BW), 
body surface area (BSA), heart rate (HR), systolic blood pressure (SBP), murmur 
grade, administration of furosemide vs non-therapy and the total dose of furosemide 
administered in mg/kg/die. 
In the prospective study dogs were sorted into groups according to the 
presence/absence of signs of worsening renal/cardiac function. The variables 
considered were: WRF, presence/absence of increasing proteinuria levels, 
radiographic parameters of heart enlargement (presence of a straight/concave caudal 
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margin of the heart, elevation of the trachea, increased VHS), presence/absence of 
increasing of furosemide’s dose administered, ACVIM class, IRIS class and the 
echocardiographic parameters LA/Ao, Cornell Index, EVmax.   
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Results  
 
The retrospective study 
 
Descriptive statistics 
Of the 2271 dogs evaluated at the Cardiology Service of the Department of Veterinary 
Science and Public Health, University of Milan, 48% were affected by CMVD. One 
hundred and fifty eight dogs of both genders (94 males and 64 females) were 
included. Of these, the 20% of males and the 65% of females were neutered. They 
were between 5 and 17 years of age (mean age 11.56 ±  2.51 years), with BW ranging 
from 2 to 48 kg (mean BW 11.52  ± 8.71 kg). The most represented breeds were 
mongrel (42%), miniature Poodle (10 %),York Shire Terrier (10 %), Shih -Tzu (6%), 
Pinscher (5%) and Dachshund (5%). Arrhythmias were described in the 18% of the 
dogs, with a prevalence of atrial fibrillation (48%) and ventricular premature 
complexes (20%). In the therapy-group (including the 70.9% of the patients) the 64% 
received furosemide associated with an ACE-inhibitor (benazepril or enalapril) and 
the 36% received triple therapy with furosemide, ACE-inhibitor and pimobendan. 
Echocardiographic values are reported in Table 1. Dogs were classified as follow: 
20.9% ACVIM B1 (asymptomatic patients that have no radiographic or 
echocardiographic evidence of cardiac remodeling in response to CMVD) , 9.5% 
ACVIM B2 (asymptomatic patients that have radiographic or echocardiographic 
evidence of cardiac remodeling in response to CMVD), 67.1% ACVIM C (patients with 
past or current clinical signs of heart failure associated with structural heart disease), 
2.5% ACVIM D (patients with end-stage disease with clinical signs of heart failure 
caused by CMVD that are refractory to ‘‘standard therapy’’); 74.7% normoazotemic 
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(sCr<1.4 mg/dl), 12.7 % IRIS 2 (early renal failure), 11.4% IRIS 3 (uremic renal 
failure), 1.3% IRIS 4 (end stage renal failure). The normoazotemic group included: 
87.9% of ACVIM B1 dogs, 100% of ACVIM B2 dogs, 67.9% of ACVIM C dogs and 50% 
of ACVIM D dogs (Fig.4). The normoazotemic-group was larger than the azotemic-
group in all the ACVIM class but the frequency of IRIS class 2 and 3 was higher in 
ACVIM class C and D.  The prevalence of CKD associated with azotemia in dogs 
affected by CMVD was 25%. The prevalence of azotemia was significantly higher in 
the therapy-group than in the non-therapy-group (32% vs 1%,  p< 0.001). The mean 
sCr value and BUN value were significantly higher in the therapy-group  than in the 
non-therapy-group (sCr: mean 1.5 vs 1.0, p<0.001; BUN: mean 83.8 vs 58.7, p=0.006).  
 
 
 
Tab. 1 Echocardiographic variables in 158 dogs with chronic mitral valve 
disease : interventricular septal thickness (IVS), left ventricular internal 
diameter (LVID), and left ventricular posterior wall thickness (LVPW) in 
diastole (d) and systole (s), aortic root diameter (Ao), left atrial diameter 
(LA), left atrial to aortic root ratio (LA/Ao), E peak velocity (EVmax), E/A 
ratio, aortic peak velocity (AoVmax) and peak gradient (AoGmax), peak 
velocity of mitral and tricuspid regurgitations (MR and TR), fractional 
shortening (FS%), left ventricular ejection fraction (EF%), End systolic 
volume index (ESVI), End diastolic volume index (EDVI)  
± 
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Inferential statistics 
The statistically significant correlations between the considered parameters are 
reported in Table 2. Simple linear regression confirmed the statistically significant 
correlation shown by the Chi-square Test and so data have not been reported there. 
Simple ordinal regression showed that considering advanced IRIS class it is possible 
to make a prediction of advanced ACVIM class and vice versa. Multiple linear and 
ordinal regressions underlined the importance of therapy for medical management of 
heart failure and of the echocardiographic parameters LA/Ao and Cornell index in 
defining ACVIM class, IRIS class, BUN and sCr.  Clinically interesting rules elaborated 
by the C5.0 [Release 2.07 GPL Edition] software were reported in Table 3. Just one 
decision tree elaborated by the same software was considered clinically useful by the 
authors (Fig. 5). 
ACVIM class 
Fig.4 Dog’s distribution in ACVIM class: 20.9% ACVIM B1, 9.5% ACVIM B2, 67.1% 
ACVIM C, 2.5% ACVIM D. Blue: normoazotemic dogs; Green: azotemic dogs. 
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Tab. 2 Statistically significant correlations 
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Rules 
 Assumption Effect 
LA/Ao >1,88 ACVIM class C 
Murmur Grade >3 ACVIM class C 
Cornell Index >1,83 ACVIM class C 
BUN <131 normoazotemic 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 3 Rules of clinical interest elaborated by  
the C5.0 [Release 2.07 GPL Edition] software 
Fig.5 Decision tree: dogs affected by CMVD where sort according to the 
echocardiographic parameter left atrium to aortic root ratio (LA/Ao) and 
according to the Cornell Index calculated over the left ventricle internal 
diameter in diastole 
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The prospective study 
 
Descriptive statistics 
Twenty one dogs affected by CMVD (cases) of both genders (12 males and 9 females) 
and 20 healthy dogs (controls) of both genders (12 males and 8 females) were 
included. They were between 6 and 15 years of age (mean age 10.3 ± 2.9 years), with 
BW ranging from 3.2 to 42 kg (mean BW 16.5 ± 11.2 kg). The most represented 
breeds were mongrel (58%), Pitbull (10%) and miniature Poodle (7%). Arrhythmias 
were described in the 19% of cases, with a prevalence of atrial premature complexes 
(75%). The 77% of cases included in the study were not receiving any drug for 
medical management of CHF before the inclusion day while the 23% of cases were under 
treatment with benazepril at presentation since less than one week. The 14% of cases began 
therapy for medical management of CHF at first evaluation with benazepril 0.5 mg/kg 
PO BID and furosemide 2 ± 0.3 mg/kg PO BID. The 33% of cases experienced at least 
one episode of CHF (switching from ACVIM class B2 to ACVIM class C), but none of 
these patients developed CKD. One case experienced three episodes of CHF in two 
years while renal function remained unaltered. The 14% of cases developed CKD 
while remaining in ACVIM class B2. The 5% of controls were affected by CKD at 
presentation (IRIS class 1) and didn’t experience worsening renal function or CHF. No 
other controls developed CKD or CMVD. Echocardiographic values are reported in 
Table 4.  
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Inferential statistics 
Considering the sorting of cases according to WRF in two groups (dogs experiencing 
WRF and dogs without WRF): there wasn’t statistically significant difference in the 
considered echocardiographic parameters or in ACVIM class between the groups.  
The simple regression test between WRF and the Cornell Index leads to a regression 
model statistically significant (p<0.001). The simple regression test between sCr 
elevations and the other considered variables did not lead to a significant model. 
 Considering the sorting of dogs according to UPC levels in two groups (dogs with 
worsening proteinuria and dogs without proteinuria or with steady proteinuria): 
there wasn’t statistically significant difference in the considered echocardiographic 
parameters or in ACVIM class between the groups. The simple regression test 
Tab.4 Tab. 1 Echocardiographic variables in 158 daogs with chronic mitral valve 
disease : left ventricular internal diameter (LVID) in diastole (d) and systole (s), aortic 
root diameter (Ao), left atrial diameter (LA), left atrial to aortic root ratio (LA/Ao), E 
peak velocity (EVmax), A peak velocity (AVmax), E/A ratio, peak velocity of mitral and 
tricuspid regurgitations (MR and TR), fractional shortening (FS%), left ventricular 
ejection fraction (EF%), Endsystolic volume index (ESVI), Enddiastolic volume index 
(EDVI), Cornell Index calculated over the LVIDd (Cornell Ind)  
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between UPC elevations and the considered variables didn’t lead to a significant 
model. 
Considering the sorting of dogs according to furosemide administration in two groups 
(dogs that increase oral administration of diuretics and dogs without therapy or 
changes in therapy): there wasn’t statistically significant difference in parameters of 
renal impairment between the groups. The simple regression test between 
furosemide’s dose increases and the considered variables didn’t lead to a significant 
model. 
Considering the sorting of dogs according to radiographic parameters of heart 
enlargement in two groups (dogs with cardiac remodeling and dogs without cardiac 
remodeling): there wasn’t statistically significant difference in IRIS class or in ACVIM 
class between the groups. The simple regression test between parameters of heart 
enlargement elevations and the considered variables didn’t lead to a significant 
model. 
There wasn’t any statistically significant difference between cases and controls in 
survival time. 
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Discussion 
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Discussion 
 
The studied population was representative of the general dogs’ population affected 
by CMVD (aged dogs of small and medium size). In this study the prevalence of CKD 
associated with azotemia complicating CMVD in dogs was assessed. Such prevalence 
was significantly higher than the prevalence of CKD calculated over the general 
population of dogs evaluated at the University of Milan (25% vs 15%, p<0.0001) and 
higher than the prevalence of CKD reported by colleagues in the dog (0.05% - 
5.8%)(Bartlett 2010, O’Neill 2013). This data suggest an influence of CMVD over renal 
impairment.  After more, therapy seems to influence renal function increasing both 
BUN and sCr even if these results may be affected by the most severe cardiac 
condition in dogs requiring medical management of HF. The amount of furosemide 
administered was correlated with BUN but not with IRIS class and sCr. This finding 
could be explained considering that in situations of compromised renal blood flow, as 
such as with cardiac disease, the increased reabsorption of BUN from within the renal 
tubule leads to serum concentrations increasing disproportionately compared to sCr  
(Medaille 2004, Boswood 2006, Nicolle 2007). The connection between class of 
cardiac failure and class of renal failure was confirmed by the statistically significant 
correlation found between the two variables (p=0.003). In case of advanced ACVIM 
class it is possible to make a prediction of advanced IRIS class (and vice versa).  This 
finding, with the statistically significant correlation found between the variable 
ACVIM class and both BUN and sCr, is of clinical importance in the management of 
patients with severe heart’s condition. Interestingly, IRIS class resulted correlated 
with the echocardiographic parameters of heart’s enlargement LA, LA/Ao and Cornell 
Index suggesting a direct connection between cardiac remodeling and renal 
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impairment. ACVIM class showed a statistically significant correlation with a large 
amount of echocardiographic parameters, as expected, and with murmur grade, as 
recently reported in veterinary literature (Ljungvall 2014). Rules and decision tree 
elaborated by the C5.0 [Release 2.07 GPL Edition] software highlighted the 
impossibility of predicting IRIS class from cardiovascular variables or ACVIM class 
from parameters of renal insufficiency. However, the decision tree elaborated by the 
software and the cut off proposed for some echocardiographic parameters 
(LA/Ao>1.88 and Cornell Index>1.83) could be of clinical interest in the management 
of HF.  The suggested BUN cut off of 131mg/dl may be useful to differentiate renal 
azotemia than pre-renal azotemia in dogs with CMVD while further studies are 
needed to confirm this hypothesis. The presence of azotemic dogs (11.1%) in ACVIM 
class B1, suggests the existence, in some dogs included in the present study, of 
primary renal damage, not due to HF influence over the renin-angiotensin-
aldosterone-system and/or over the neurohormonal systems activation.  In these 
patients renal impairment and CMVD probably just coexisted.  
The prospective study assessed the most common used parameters of renal 
insufficiency sCr, BUN and UPC (associated with urine specific gravity) periodically in 
a three years period and in well-controlled conditions. It denies the hypothesized 
cardio-renal connection supported by the retrospective study. None of the cases 
included experienced both CHF and renal damage in the study period. Considering 
our expectation, multiple CHF events experienced by some patients should have 
affected renal function. The persistence of optimal renal condition regardless of CHF 
events and therapy administration is in contrast with the previous results. The 
statistical analysis revealed a cause-effect relation between WRF and the Cornell 
Index calculated over the LVIDd. This data suggest a link between cardiac remodeling, 
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and in particular left ventricle enlargement, and renal function. To authors ‘opinion, 
the use of WRF, better than single sCr and BUN levels, may highlight the existence of a 
cardio-renal connection. However the small number of cases included in this 
prospective study represents a great limit. We consider this work a pilot study. 
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Limitations  
 
The main limitations of this retrospective study are due to the retrospective nature of 
the study itself. Type 2 and type 4 patients could not be certainly differentiated. The 
small sample size and the underrepresented ACVIM class B2 could have affect some 
results. The lack of biomarkers of early renal injury, of urine examination and of 
abdomen ultrasound made us underestimate the real prevalence of CKD. 
The main limitations of this prospective study are related to the small sample size. 
The restrictive inclusion criteria require a longer period of inclusion. Dogs receiving 
benazepril at presentation would have needed a withdrawal of therapy before 
inclusion to reduce the influence of the drugs on UPC and other parameters at 
baseline. 
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Conclusions 
 
In conclusion, these results demonstrate that the prevalence of CKD associated with 
azotemia in dogs affected by CMVD is 25%, higher than the prevalence in the general 
population.  There is a statistically significant direct correlation between ACVIM and 
IRIS class. Dogs in advanced ACVIM class and receiving therapy for medical 
management of CHF are commonly affected by concomitant CKD. The Cornell Index, 
and so left ventricle enlargement, is correlated with WRF.  Experiencing CHF seems 
not to directly affect renal function. 
Further investigations are needed to define if CMVD or the administration of drugs 
for medical management of CHF can directly affect renal function inducing and/or 
worsening dysfunction of the kidneys. 
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